- Immunome Inc (NASDAQ:IMNM) has submitted an Investigational New Drug (IND) application to the FDA for IMM-BCP-01, a three-antibody cocktail, for the treatment of COVID-19.
- IMM-BCP-01 is a three-antibody cocktail targeting non-overlapping regions of the Spike protein.
- It elicits multi-modal activity in preclinical testing, including ACE2 and non-ACE2 dependent neutralization and inducing natural viral clearance mechanisms.
- Related Link: Immunome’s COVID-19 Antibody Neutralizes Two Variant Strains In Animal Studies.
- The cocktail significantly reduces the viral load in the lungs of the hamsters infected with SARS-CoV-2. It broadly neutralizes current and former variants of concern, including the Delta variant, in in vitro testing.
- Immunome plans to initiate a placebo-controlled dose-escalation study of IMM-BCP-01 in patients infected with SARS-CoV-2.
- See here Benzinga’s Full FDA Calendar.
- Price Action: IMNM shares are down 9.37% at $18.56 during the market session on the last check Monday.
Raymond James Maintains Strong Buy on Synnex, Raises Price Target to $140
Raymond James analyst Adam Tindle maintains Synnex (NYSE:SNX) with a Strong Buy and raises the price target from $125 to $140.
